National Action Plan For The MHPSS Response To COVID-19

National Action Plan for the MHPSS Response to COVID-19

This action plan was developed as part of the national response to the COVID-19 outbreak. It aims at comprehensively addressing the MHPSS aspects of the COVID-19 outbreak in Lebanon for all persons living in the country. It was developed by the MOPH-National Mental Health Programme (NMHP) with WHO and UNICEF, in line with the IASC Briefing note on addressing mental health and psychosocial aspects of COVID-19 Outbreak- version 1.0 and the local needs, health system and national mental health strategy.

Goals:

Promote mental health and mitigate COVID-19 related stressors including stigma and discrimination against persons affected and health workers.
Provide mental health support to the persons in quarantine in the hospital or at home and their families.
Support the mental health of health workers and first responders in the response.
Ensure continuity of mental health care for persons using mental health services in line with IPC guidelines.

To view the action plan, click here: National Action Plan for MHPSS Response to COVID-19

All

ATC	Name	B/G	Ingredients ↑	Dosage	Form	Price
G04CA01	XATRAL XL	B	Alfuzosin HCl - 10mg	10mg	Tablet, prolonged release	1,061,636 L.L
N05BA12	XANAX	B	Alprazolam - 0.5mg	0.5mg	Tablet	477,064 L.L
N05AX12	XALIPRO	G	Aripiprazole - 10mg	10mg	Tablet	2,123,271 L.L
N05AX12	XALIPRO	G	Aripiprazole - 15mg	15mg	Tablet	2,418,917 L.L
N05AX12	XALIPRO	G	Aripiprazole - 5mg	5mg	Tablet	1,746,995 L.L
L01BC06	XELODA	B	Capecitabine - 500mg	500mg	Tablet, film coated	17,946,398 L.L
J01DD15	XEVANEER	G	Cefdinir - 125mg/5ml	125mg/5ml	Powder for suspension	1,308,903 L.L
J01DD15	XEVANEER	G	Cefdinir - 125mg/5ml	125mg/5ml	Powder for suspension	686,704 L.L
J01DD15	XEVANEER	G	Cefdinir - 300mg	300mg	Capsule	1,350,562 L.L
M03AX01	XEOMIN	BioTech	Clostridium botulinum type A neurotoxin complex - 100 units LD50	100 units LD50	Injectable powder for solution	20,517,541 L.L
M03AX01	XEOMIN	BioTech	Clostridium botulinum type A neurotoxin complex - 50 units LD50	50 units LD50	Injectable powder for solution	11,920,109 L.L
L01ED01	XALKORI	B	Crizotinib - 200mg	200mg	Capsule	347,644,061 L.L
L01ED01	XALKORI	B	Crizotinib - 250mg	250mg	Capsule	347,644,061 L.L
L01ED01	XALKORI	B	Crizotinib - 250mg	250mg	Capsule	L.L
M05BX04	XGEVA	BioTech	Denosumab - 120mg	120mg	Injectable solution	33,545,669 L.L
L02BB04	XTANDI	B	Enzalutamide - 40mg	40mg	Capsule, soft	278,248,572 L.L
C10AX09	XIMACOL	G	Ezetimibe - 10mg	10mg	Tablet	1,894,818 L.L
A10AE56	XULTOPHY	BioTech	Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml		Injectable solution	13,503,847 L.L
A10AE56	XULTOPHY	BioTech	Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml		Injectable solution	13,503,847 L.L
S01EE01	XALAPROST	G	Latanoprost - 0.005% w/v	0.005% w/v	Drops solution	421,967 L.L
S01EE01	XALATAN	B	Latanoprost - 50mcg/ml	50mcg/ml	Drops solution	704,173 L.L
R06AE09	XYZAL	B	Levocetirizine dihydrochloride - 5mg	5mg	Tablet, film coated	572,477 L.L
D04AB01	XYLOCAINE	B	Lidocaine - 10mg/spray dose	100mg/ml	Spray	667,890 L.L
A10BD15	XIGDUO XR	B	Metformin HCl XR - 1000mg, Dapagliflozin - 10mg		Tablet	3,006,579 L.L
A10BD15	XIGDUO XR	B	Metformin HCl XR - 1000mg, Dapagliflozin - 5mg		Tablet	3,867,041 L.L
D07AC13	XEMADERM	G	Mometasone furoate - 0.1%	0.1%	Cream	335,961 L.L
B02BD02	XYNTHA	BioTech	Moroctocog alfa - 500IU	500IU	Injectable lyophilised powder for solution+diluent	23,067,288 L.L
B02BD02	XYNTHA	BioTech	Moroctocog alfa - 500IU	500IU	Injectable lyophilised powder for solution+diluent	L.L
B02BD02	XYNTHA	BioTech	Moroctocog alfa - 500IU	500IU	Injectable lyophilised powder for solution+diluent	L.L
R03DX05	XOLAIR	BioTech	Omalizumab - 150mg	150mg	Injectable solution	L.L